UTHR Q1 2024 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$678M+33.7% YoY

Gross Profit

$605M89.2% margin

Operating Income

$356M52.6% margin

Net Income

$307M45.2% margin

EPS (Diluted)

$6.17

QoQ Revenue Growth

+10.2%

Cash Flow

Operating Cash Flow

$377M

Free Cash Flow

$338M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$6.5B

Total Liabilities

$1.2B

Stockholders' Equity

$5.3B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$678M	$507M	+33.7%
Gross Profit	$605M	$455M	+33.0%
Operating Income	$356M	$284M	+25.3%
Net Income	$307M	$241M	+27.3%

Revenue Segments

Tyvaso

$373M55%

Remodulin

$128M19%

Orenitram

$106M16%

Unituxin

$58M9%

Adcirca

$6M1%

Product and Service, Other

$6M1%

Geographic Segments

UNITED STATES

$642M95%

Non-US

$36M5%